Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 23, Issue 12, Pages 1637-1654
Publisher
Informa Healthcare
Online
2014-08-19
DOI
10.1517/13543784.2014.951435
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EORTC 22071-24071: Randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence.
- (2017) C. Liberatoscioli et al. JOURNAL OF CLINICAL ONCOLOGY
- Head and Neck Cancers, Version 2.2013
- (2017) David G. Pfister et al. Journal of the National Comprehensive Cancer Network
- Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
- (2015) Mari Iida et al. NEOPLASIA
- Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
- (2014) J. B. Vermorken et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Erlotinib, Erlotinib-Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
- (2014) N. D. Gross et al. CLINICAL CANCER RESEARCH
- Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
- (2014) A. Psyrri et al. CLINICAL CANCER RESEARCH
- PARAMOUNT Trial: Reopening a Window to Maintenance Therapy
- (2014) Sandro Barni et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic Study
- (2013) N. F. Saba et al. Cancer Prevention Research
- Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
- (2013) Roger B. Cohen CANCER TREATMENT REVIEWS
- Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions
- (2013) Sandra Schmitz et al. CANCER TREATMENT REVIEWS
- Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies
- (2013) D. M. Shin et al. CLINICAL CANCER RESEARCH
- Head and neck cancer: from anatomy to biology
- (2013) Pinaki Bose et al. INTERNATIONAL JOURNAL OF CANCER
- Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
- (2013) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee
- (2013) Aaron R. Weiss et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial
- (2013) Renato G. Martins et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
- (2013) Jean Louis Lefebvre et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
- (2013) Jan B Vermorken et al. LANCET ONCOLOGY
- Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
- (2013) S. Huang et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Comparison of Near-Infrared-Labeled Cetuximab and Panitumumab for Optical Imaging of Head and Neck Squamous Cell Carcinoma
- (2013) Kristine E. Day et al. MOLECULAR IMAGING AND BIOLOGY
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab
- (2013) Ferdows Ather et al. PLoS One
- Head and neck cancer
- (2012) J. Giralt et al. ANNALS OF ONCOLOGY
- A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
- (2012) A. R. Abdul Razak et al. ANNALS OF ONCOLOGY
- Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
- (2012) A. Argiris et al. ANNALS OF ONCOLOGY
- Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells
- (2012) Jorge Ernesto González et al. CANCER BIOLOGY & THERAPY
- Abstract 2506: A phase 1 study of ABT-806, a humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors
- (2012) James M. Cleary et al. CANCER RESEARCH
- Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
- (2012) S. Huang et al. CANCER RESEARCH
- Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma
- (2012) S. Wheeler et al. CLINICAL CANCER RESEARCH
- A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2012) J. A. de Souza et al. CLINICAL CANCER RESEARCH
- Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease
- (2012) Kevin Harrington et al. EUROPEAN JOURNAL OF CANCER
- The role of cetuximab in the management of head and neck cancers
- (2012) Peyman Kabolizadeh et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase 1 Study of Erlotinib Plus Radiation Therapy in Patients With Advanced Cutaneous Squamous Cell Carcinoma
- (2012) C. Hope Heath et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Graft-Versus-Host Disease: Have We Solved the Problem?
- (2012) Sergio Giralt JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer
- (2012) Arlene A. Forastiere et al. JOURNAL OF CLINICAL ONCOLOGY
- Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature
- (2012) Guilherme Rabinowits et al. ORAL ONCOLOGY
- EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma
- (2012) Yassine Lalami et al. RADIOTHERAPY AND ONCOLOGY
- Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial
- (2011) F. Arias de la Vega et al. ANNALS OF ONCOLOGY
- Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck
- (2011) J M del Campo et al. BRITISH JOURNAL OF CANCER
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor
- (2011) Niels Jørgen Østergaard Skartved et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
- (2011) P. A. Janne et al. CLINICAL CANCER RESEARCH
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance
- (2011) Rebekka Krumbach et al. EUROPEAN JOURNAL OF CANCER
- Zalutumumab in head and neck cancer
- (2011) Ulrike Schick et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors
- (2011) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
- (2011) Jean-Pascal Machiels et al. LANCET ONCOLOGY
- Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial
- (2011) Jochen H Lorch et al. LANCET ONCOLOGY
- The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab–bevacizumab–irradiation combination on head and neck cancer xenografts
- (2011) Alexandre Bozec et al. ORAL ONCOLOGY
- Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: A phase II, randomized, double-blind, placebo-controlled study
- (2011) Vincent Gregoire et al. RADIOTHERAPY AND ONCOLOGY
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
- (2010) Marta Osorio Rodríguez et al. CANCER BIOLOGY & THERAPY
- Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers
- (2010) Lei Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
- (2010) M. W. Pedersen et al. CANCER RESEARCH
- Emerging drugs to treat squamous cell carcinomas of the head and neck
- (2010) Christopher Fung et al. EXPERT OPINION ON EMERGING DRUGS
- Phase I/II Study of Erlotinib Combined With Cisplatin and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- (2010) Daniel Herchenhorn et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Concurrent Cisplatin and Radiation Versus Cetuximab and Radiation for Locally Advanced Head-and-Neck Cancer
- (2010) Lawrence Koutcher et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding resistance to EGFR inhibitors—impact on future treatment strategies
- (2010) Deric L. Wheeler et al. Nature Reviews Clinical Oncology
- Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
- (2010) K. Kian Ang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma
- (2010) Kondo ONCOLOGY REPORTS
- Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma
- (2010) Chunrong Li et al. RADIOTHERAPY AND ONCOLOGY
- Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
- (2009) L. J. Wirth et al. ANNALS OF ONCOLOGY
- A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck
- (2009) Francesco Caponigro et al. ANTI-CANCER DRUGS
- Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck
- (2009) John D. Hainsworth et al. CANCER
- Phase I Study of Lapatinib in Combination With Chemoradiation in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- (2009) Kevin J. Harrington et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
- (2009) J. Simon W. Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation
- (2009) Y. Pointreau et al. JNCI-Journal of the National Cancer Institute
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
- (2009) Ezra EW Cohen et al. LANCET ONCOLOGY
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
- (2009) James A Bonner et al. LANCET ONCOLOGY
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
- (2009) Jean-Pierre Pignon et al. RADIOTHERAPY AND ONCOLOGY
- HPV & head and neck cancer: a descriptive update
- (2009) Peter KC Goon et al. Head and Neck Optical Diagnostics Society
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
- Locoregionally Advanced Head and Neck Cancer Treated With Primary Radiotherapy: A Comparison of the Addition of Cetuximab or Chemotherapy and the Impact of Protocol Treatment
- (2008) Jimmy J. Caudell et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck Cancers
- (2008) Maura L. Gillison et al. JNCI-Journal of the National Cancer Institute
- Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
- (2008) A. J. Gonzales et al. MOLECULAR CANCER THERAPEUTICS
- Recent Advances in Head and Neck Cancer
- (2008) Robert I. Haddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility
- (2008) J. J. Lammerts van Bueren et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Validation of HB-EGF and amphiregulin as targets for human cancer therapy
- (2007) Fusanori Yotsumoto et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started